edoxaban Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
blood coagulation factor XA inhibitors, antithrombotics 4897 480449-70-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • edoxaban tosylate
  • edoxaban
  • edoxaban tosilate
  • edoxaban tosilate hydrate
  • lixiana
  • DU-176b
  • savaysa
An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Edoxaban is administered as edoxaban tosylate. This agent has an elimination half-life of 9-11 hours and undergoes renal excretion.
  • Molecular weight: 548.06
  • Formula: C24H30ClN7O4S
  • CLOGP: 0.15
  • LIPINSKI: 2
  • HAC: 11
  • HDO: 3
  • TPSA: 136.63
  • ALOGS: -4.68
  • ROTB: 6

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 1.53 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.19 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.50 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 6.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 19, 2015 EMA Daiichi Sankyo Europe GmbH
Jan. 8, 2015 FDA DAIICHI SANKYO
April 22, 2011 PMDA DAIICHI SANKYO COMPANY, Limited

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 267.06 22.90 201 7814 146741 53194310
Anaemia 132.55 22.90 184 7831 276534 53064517
Haematochezia 114.21 22.90 74 7941 42284 53298767
Atrial fibrillation 92.17 22.90 98 7917 111554 53229497
Lymphatic fistula 85.16 22.90 21 7994 877 53340174
Femoral hernia incarcerated 84.84 22.90 21 7994 891 53340160
Arterial haemorrhage 84.28 22.90 24 7991 1752 53339299
Melaena 83.71 22.90 53 7962 29076 53311975
Cardiac failure 81.02 22.90 81 7934 85763 53255288
Pancreatic steatosis 80.95 22.90 21 7994 1078 53339973
Product monitoring error 80.64 22.90 26 7989 2891 53338160
Pallor 80.41 22.90 49 7966 25133 53315918
Wound infection pseudomonas 74.94 22.90 21 7994 1446 53339605
Labelled drug-drug interaction medication error 73.89 22.90 35 7980 10864 53330187
Arrhythmia 70.24 22.90 52 7963 36727 53304324
Aortic valve stenosis 69.73 22.90 24 7991 3264 53337787
Haematuria 67.77 22.90 46 7969 28343 53312708
Seroma 66.87 22.90 21 7994 2144 53338907
Haemarthrosis 65.99 22.90 23 7992 3247 53337804
Drug ineffective 65.35 22.90 21 7994 817224 52523827
Tachyarrhythmia 64.83 22.90 25 7990 4691 53336360
Renal impairment 58.10 22.90 67 7948 83251 53257800
Eructation 55.62 22.90 26 7989 7829 53333222
Gastrointestinal haemorrhage 51.69 22.90 62 7953 80268 53260783
Faecaloma 51.41 22.90 25 7990 8216 53332835
Wound dehiscence 51.21 22.90 21 7994 4625 53336426
Hyperkalaemia 50.78 22.90 51 7964 54205 53286846
Diverticulum intestinal 50.48 22.90 23 7992 6534 53334517
Hepatic cyst 49.74 22.90 21 7994 4975 53336076
Aortic arteriosclerosis 49.52 22.90 22 7993 5892 53335159
Inflammatory marker increased 48.56 22.90 22 7993 6168 53334883
Cerebral infarction 45.40 22.90 34 7981 24410 53316641
Internal haemorrhage 44.30 22.90 19 7996 4677 53336374
Aplastic anaemia 42.37 22.90 22 7993 8299 53332752
Groin pain 42.28 22.90 23 7992 9525 53331526
Oedema peripheral 40.30 22.90 83 7932 170704 53170347
Postoperative wound infection 40.14 22.90 22 7993 9244 53331807
Hyponatraemia 39.93 22.90 64 7951 108543 53232508
Anuria 39.16 22.90 24 7991 12416 53328635
Dyspnoea 38.73 22.90 182 7833 586050 52755001
Bradycardia 37.98 22.90 50 7965 71006 53270045
Myelodysplastic syndrome 37.39 22.90 26 7989 16634 53324417
Escherichia infection 37.30 22.90 23 7992 12027 53329024
Chorea 36.36 22.90 12 8003 1435 53339616
Decreased appetite 35.78 22.90 91 7924 214883 53126168
Joint dislocation 34.29 22.90 22 7993 12323 53328728
Cardiovascular disorder 34.18 22.90 22 7993 12391 53328660
Cardiogenic shock 33.99 22.90 25 7990 17457 53323594
Tricuspid valve incompetence 33.56 22.90 23 7992 14373 53326678
Tachycardia 33.42 22.90 59 7956 108153 53232898
Angina pectoris 32.53 22.90 30 7985 28695 53312356
Mitral valve incompetence 31.50 22.90 25 7990 19526 53321525
Pulmonary hypertension 31.18 22.90 33 7982 37237 53303814
Left ventricular dysfunction 31.15 22.90 20 7995 11217 53329834
Rhonchi 30.02 22.90 12 8003 2474 53338577
Pain 29.61 22.90 27 7988 588371 52752680
Syncope 29.48 22.90 57 7958 111936 53229115
Embolic stroke 28.22 22.90 13 8002 3786 53337265
Product prescribing error 27.93 22.90 25 7990 23006 53318045
Sopor 27.80 22.90 24 7991 21060 53319991
Gastroenteritis clostridial 27.36 22.90 8 8007 641 53340410
Urinary retention 27.06 22.90 27 7988 28439 53312612
Osteopenia 26.47 22.90 22 7993 18333 53322718
Streptococcal sepsis 26.14 22.90 10 8005 1835 53339216
Electrolyte imbalance 25.92 22.90 22 7993 18862 53322189
Hiatus hernia 25.19 22.90 22 7993 19598 53321453
Oesophageal mucosal tear 24.58 22.90 4 8011 17 53341034
Dysuria 23.78 22.90 26 7989 30427 53310624
Anal haemorrhage 23.34 22.90 9 8006 1687 53339364
Subdural haematoma 22.98 22.90 18 7997 13795 53327256

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 103.58 20.61 119 6155 115140 32392112
Pelvic mass 97.57 20.61 19 6255 195 32507057
Haematuria 78.66 20.61 69 6205 48292 32458960
Cardiac failure 76.17 20.61 91 6183 91582 32415670
Prostate cancer recurrent 74.38 20.61 20 6254 915 32506337
Blood urea abnormal 72.23 20.61 19 6255 798 32506454
Malignant transformation 72.09 20.61 19 6255 804 32506448
Cerebral infarction 69.69 20.61 51 6223 27563 32479689
Blood electrolytes abnormal 68.52 20.61 19 6255 976 32506276
Atrial fibrillation 63.25 20.61 94 6180 116610 32390642
Melaena 61.49 20.61 52 6222 34613 32472639
Anaemia 60.51 20.61 133 6141 223491 32283761
Renal impairment 52.56 20.61 76 6198 91896 32415356
Haematochezia 48.38 20.61 48 6226 39160 32468092
Oedema peripheral 46.81 20.61 81 6193 114010 32393242
Interstitial lung disease 46.63 20.61 60 6214 64941 32442311
Respiratory tract haemorrhage 45.71 20.61 14 6260 1021 32506231
Hydronephrosis 37.00 20.61 23 6251 9500 32497752
Dyspnoea 36.57 20.61 152 6122 361893 32145359
Embolic stroke 34.18 20.61 16 6258 3758 32503494
Labelled drug-drug interaction medication error 33.74 20.61 24 6250 12389 32494863
Drug ineffective 32.26 20.61 17 6257 383460 32123792
Procedural failure 30.34 20.61 6 6268 67 32507185
Pallor 30.05 20.61 29 6245 22852 32484400
Haemorrhage 28.39 20.61 41 6233 49407 32457845
Epistaxis 27.36 20.61 43 6231 55812 32451440
Cerebral haemorrhage 26.35 20.61 33 6241 34714 32472538
Pulmonary alveolar haemorrhage 24.65 20.61 16 6258 7113 32500139
Duodenal ulcer haemorrhage 24.49 20.61 14 6260 4960 32502292
Haemoptysis 22.54 20.61 30 6244 33495 32473757
Stress urinary incontinence 22.24 20.61 5 6269 107 32507145
Skin irritation 22.20 20.61 13 6261 4818 32502434
Haematoma 22.09 20.61 26 6248 25658 32481594
Tracheal pain 21.22 20.61 4 6270 34 32507218

Pharmacologic Action:

SourceCodeDescription
ATC B01AF03 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Direct factor Xa inhibitors
MeSH PA D000925 Anticoagulants
MeSH PA D000991 Antithrombins
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D065427 Factor Xa Inhibitors
MeSH PA D006401 Hematologic Agents
MeSH PA D011480 Protease Inhibitors
MeSH PA D015842 Serine Proteinase Inhibitors
FDA MoA N0000175635 Factor Xa Inhibitors
FDA EPC N0000175637 Factor Xa Inhibitor
CHEBI has role CHEBI:50249 anticoagulante
CHEBI has role CHEBI:50427 platelet aggregation inhibitors
CHEBI has role CHEBI:68581 coagulation factor Xa inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Pulmonary embolism indication 59282003 DOID:9477
Embolism indication 414086009
Ischemic stroke indication 422504002
Prevention of deep vein thrombosis indication 439993001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.7 acidic
pKa2 12.4 acidic
pKa3 6.8 Basic
pKa4 3.01 Basic
pKa5 2.14 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 15MG BASE SAVAYSA DAIICHI SANKYO INC N206316 Jan. 8, 2015 RX TABLET ORAL Aug. 9, 2022 INFORMATION ADDED TO LABELING FROM PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH CANCER
EQ 30MG BASE SAVAYSA DAIICHI SANKYO INC N206316 Jan. 8, 2015 RX TABLET ORAL Aug. 9, 2022 INFORMATION ADDED TO LABELING FROM PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH CANCER
EQ 60MG BASE SAVAYSA DAIICHI SANKYO INC N206316 Jan. 8, 2015 RX TABLET ORAL Aug. 9, 2022 INFORMATION ADDED TO LABELING FROM PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH CANCER

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Coagulation factor X Enzyme INHIBITOR Ki 9.25 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
D09546 KEGG_DRUG
480449-71-6 SECONDARY_CAS_RN
4034081 VANDF
CHEBI:85974 CHEBI
CHEMBL1269025 ChEMBL_ID
CHEMBL2105682 ChEMBL_ID
C552171 MESH_SUPPLEMENTAL_RECORD_UI
7575 IUPHAR_LIGAND_ID
8982 INN_ID
DB09075 DRUGBANK_ID
NDU3J18APO UNII
10280735 PUBCHEM_CID
1599538 RXNORM
232451 MMSL
30841 MMSL
30865 MMSL
d08338 MMSL
015852 NDDF
015853 NDDF
712778008 SNOMEDCT_US
714687009 SNOMEDCT_US
C2975435 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SAVAYSA HUMAN PRESCRIPTION DRUG LABEL 1 65597-201 TABLET, FILM COATED 15 mg ORAL NDA 34 sections
SAVAYSA HUMAN PRESCRIPTION DRUG LABEL 1 65597-202 TABLET, FILM COATED 30 mg ORAL NDA 34 sections
SAVAYSA HUMAN PRESCRIPTION DRUG LABEL 1 65597-203 TABLET, FILM COATED 60 mg ORAL NDA 34 sections